Sempra (SRE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Annual meeting scheduled for May 12, 2026, to be held virtually, with shareholders voting on four key proposals.
2025 saw strong operational and financial performance, with $13 billion invested in infrastructure and a focus on regulated utilities in California and Texas.
Strategic initiatives included divesting non-core assets, modernizing infrastructure, and enhancing operational excellence.
Board and management emphasize long-term value creation, strong governance, and stakeholder engagement.
Voting matters and shareholder proposals
Proposal 1: Election of 11 director nominees, with 82% independence and 64% women or people of color; board recommends FOR.
Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for 2026; board recommends FOR.
Proposal 3: Advisory approval of executive compensation; board recommends FOR.
Proposal 4: Shareholder proposal for an independent board chairman; board recommends AGAINST, citing strong governance and flexibility.
Board of directors and corporate governance
Board comprises 11 nominees with diverse backgrounds and an average tenure of 6.9 years.
82% of directors are independent; all NYSE-required committees are 100% independent.
Lead Independent Director role is robust, with defined responsibilities and active shareholder engagement.
Annual board and committee evaluations, director overboarding policy, and mandatory retirement at age 75 or 15 years of service.
Board refreshment ongoing, with two new directors added in 2025.
Latest events from Sempra
- Key votes include director elections, auditor ratification, and a proposal for an independent chairman.SRE
Proxy filing27 Mar 2026 - $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025